.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers recently investigated new options for metastatic urothelial carcinoma treatment in patients ineligible for cisplatin. This randomized Phase II trial compared gemcitabine and nivolumab combined with either carboplatin or oxaliplatin. Although oxaliplatin showed promise in preclinical cancer models due to its immunomodulatory properties, clinical outcomes favored the carboplatin-based regimen.
Clinicians often face difficulty when managing advanced urothelial cancer in patients with renal impairment. Consequently, identifying effective alternatives to cisplatin is vital. Specifically, this trial aimed to see if oxaliplatin could better sensitize tumors to immune checkpoint blockade than traditional carboplatin. However, the study results challenged these earlier laboratory assumptions.
The trial randomized 49 patients to evaluate efficacy and safety. The carboplatin arm achieved a robust objective response rate (ORR) of 69.6%. In contrast, the oxaliplatin arm reached only 33.3%. Furthermore, the median overall survival was significantly longer for patients receiving carboplatin, reaching 24.74 months compared to 16.43 months for the oxaliplatin group. Therefore, carboplatin remains the preferred backbone for chemo-immunotherapy in this setting.
Biomarker analyses provided additional clarity regarding these differences. The carboplatin arm exhibited sustained adaptive immune activation, which supports long-term tumor control. Conversely, the oxaliplatin arm showed features suggestive of tumor-promoting inflammation. These inflammatory characteristics likely hindered the effectiveness of the nivolumab combination.
This study demonstrates that preclinical potential does not always translate into clinical success. While oxaliplatin was theorized to be a superior immunomodulator, it did not outperform carboplatin. Consequently, gemcitabine and carboplatin plus nivolumab remains a strong consideration for cisplatin-ineligible patients. Ongoing research continues to refine metastatic urothelial carcinoma treatment to improve survival outcomes further.
Despite preclinical data suggesting oxaliplatin might enhance immunotherapy, clinical results showed it promoted tumor-promoting inflammation. Carboplatin, however, stimulated adaptive immune activation, leading to a much higher response rate of 69.6%.
In this Phase II trial, patients in the carboplatin arm had a median overall survival of 24.74 months. This was significantly higher than the 16.43 months observed in the oxaliplatin arm, reinforcing carboplatin as the more effective chemotherapy partner.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Professional consultation is required for any health concerns or before making medical decisions. Refer to the latest local and national guidelines for clinical practice.
References
Li Z et al. Gemcitabine plus nivolumab with carboplatin or oxaliplatin in cisplatin-ineligible patients with metastatic urothelial carcinoma: a randomized phase II trial. Clin Cancer Res. 2026 Apr 19. doi: 10.1158/1078-0432.CCR-26-0469. PMID: 42001507.
Galsky MD et al. Treatment of Metastatic Urothelial Carcinoma in Cisplatin-Ineligible Patients. Journal of Clinical Oncology. 2024.
Indian Council of Medical Research. Consensus Document for Management of Urinary Bladder Cancer. 2023.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A Phase II trial shows carboplatin-based chemo-immunotherapy significantly outperforms oxaliplatin in cisplatin-ineligible metastatic urothelial carcinoma....
4 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
